The Claim
In adults with atherosclerosis or diabetes and LDL cholesterol ≥90 mg/dL but no prior heart attack or stroke, monthly subcutaneous evolocumab (140 mg every two weeks) for a median of 4.6 years reduces the risk of first major cardiovascular events—defined as death from coronary heart disease, myocardial infarction, or ischemic stroke—by 25% compared to placebo, with a hazard ratio of 0.75.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with high cholesterol, atherosclerosis, or diabetes who have not had a heart attack or stroke, receiving evolocumab injections every two weeks for about 4.6 years reduces the rate of first heart attacks, strokes, or deaths from heart disease by 25% compared to no treatment.
See the scientific wording
In adults with atherosclerosis or diabetes and LDL cholesterol ≥90 mg/dL but no prior heart attack or stroke, monthly subcutaneous evolocumab (140 mg every two weeks) for a median of 4.6 years reduces the risk of first major cardiovascular events—defined as death from coronary heart disease, myocardial infarction, or ischemic stroke—by 25% compared to placebo, with a hazard ratio of 0.75, indicating a clinically significant causal benefit in this high-risk population.
A drug binds to a protein that normally destroys cholesterol-clearing receptors in the liver. This allows more receptors to stay on the liver surface, pulling more cholesterol out of the blood. Lower cholesterol in the blood stops new fatty buildup in artery walls and stabilizes existing plaques, preventing blockages that cause heart attacks and strokes.
What the research says
1 studyStudy: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
For people with high cholesterol due to diabetes or clogged arteries but no prior heart attack or stroke, getting evolocumab shots every two weeks for almost five years lowered their chance of having a first heart attack, stroke, or dying from heart disease by about 25% compared to those who didn’t get the drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.